Such disease heterogeneity makes comparison of trials between geographic regions and with differing composition of diseases (gallbladder, intra- and extrahepatic tumours) challenging.
Overall, using our sampling approach, we show that the functional composition of a disease set is an important factor in its observed topological properties, but that the broad disease group (e.g., Mendelian disorders vs. cancer) and the type of involvement (e.g., mutation vs. altered expression in cancer) play significant roles as well.
An appreciation for this composition of metastatic disease must filter down to the study of proteomic alterations, not simply stratified by progression through discrete disease stages, but also within-stage subtypes.
Having determined that the functional composition of the disease sets can potentially play a role in the differences that set them apart from non-disease genes, we next test whether this is indeed the case by comparing disease sets with function-constrained samples generated as described above.
We find that our sampling procedure effectively reduces the differences between the functional composition of the disease set and that of the function-constrained samples; in contrast, we observe a substantial deviation of the per-term distribution in the unconstrained samples as compared to the target distribution arising from the disease set.
In addition, we examined the composition of the disease-specific transcripts and found a high level of NAT expression both in vitro and clinically in this disease setting.
Additionally, the composition of NADs in disease and their biological relevance are not well understood.
The current study was designed to comprehensively address this issue by analyzing the clinical findings and, especially, the genetic composition of ABCA4-associated disease in African Americans.
The current study analyses the age- and sex-composition of the disease-related mortality in the two outbreaks and draws conclusions about disease dynamics and immunity.
